# Eloralintide and the EloraTZP trial Canonical: https://europeanpeptideshop.com/blog/eloralintide-tirzepatide-eloratzp-trial/ Explore the catalogue and research library. Ordering and shipping have not opened yet. Research news · 8 November 2026 · 3 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/) ### On this page EloraTZP is the investigational combination of eloralintide and tirzepatide. Lilly reported Phase 2b results on September 30, 2026. The central distinction is simple: evidence for the combination is not the same as evidence for eloralintide alone. [1](https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide) ## What is being combined? Eloralintide is a selective amylin receptor agonist, while tirzepatide targets GIP and GLP-1 receptors. Lilly's program examines whether the two together can produce additional effects. That does not make eloralintide another name for tirzepatide or retatrutide. [1](https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide) A useful comparison should identify the molecule or combination before discussing an outcome. Otherwise, a result from a combination arm can easily be attached to the wrong compound. ## Who took part in the study? The ClinicalTrials.gov record for NCT06603571 describes a randomized, double-blind, parallel-group Phase 2 study in adults with overweight or obesity and type 2 diabetes. It lists 367 actual participants and body-weight change at 48 weeks as the primary outcome. HbA1c and pharmacokinetic measurements appear among secondary outcomes. [2](https://clinicaltrials.gov/study/NCT06603571) The registry records the study as completed, with its latest posted update dated September 29. That identifies this particular trial's status; it does not mean the wider development program is complete. [2](https://clinicaltrials.gov/study/NCT06603571) ## What did the sponsor report? Lilly reported average weight change of up to −23.3% in a combination arm versus −14.8% with tirzepatide 15 mg, using its efficacy estimand. It also reported more frequent gastrointestinal events in combination arms and adverse-event discontinuation rates ranging from 10.8% to 27.0% for EloraTZP. [1](https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide) Efficacy and tolerability belong in the same reading of the result. A single maximum percentage omits the study population, analysis assumptions and people who stopped treatment. The numbers are trial findings, not personal-use instructions. ## What stage has the program reached? Lilly's pipeline dated October 29 lists eloralintide in Phase 3 for obesity and an eloralintide incretin add-on program. The separate Phase 2b announcement describes plans for a co-formulation program. Current pipeline status should be checked directly when reporting a new milestone. [3](https://www.lilly.com/science/research-development/pipeline) [1](https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide) A molecule, a combination regimen and a finished co-formulation can be related parts of development while remaining different things. Keep their names and trial identifiers visible rather than shortening all of them to one headline. ## Can these percentages be ranked against retatrutide? This study is not a direct EloraTZP-versus-retatrutide comparison. A comparison of percentages across separate trials would also have to account for differences in participants, duration, comparator and analysis. It cannot supply the answer that a randomized head-to-head study would be designed to test. [2](https://clinicaltrials.gov/study/NCT06603571) The more useful next questions are whether later trials reproduce the findings, how tolerability compares under their protocols, and what endpoints are eventually reviewed by regulators. Those questions keep the development story specific without assuming an approval or a treatment advantage. ## Scope for European readers This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the [research-use statement](https://europeanpeptideshop.com/research-use/) for the storefront's scope. ## Laboratory research only Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here. ## References - [Lilly: EloraTZP Phase 2b results, September 30, 2026](https://investor.lilly.com/news-releases/news-release-details/lillys-eloratzp-combination-eloralintide-and-tirzepatide) - [ClinicalTrials.gov: NCT06603571](https://clinicaltrials.gov/study/NCT06603571) - [Lilly clinical development pipeline, October 29, 2026](https://www.lilly.com/science/research-development/pipeline) ## More articles Research news · 3 min read ## [Avexitide and the LUCIDITY trial](https://europeanpeptideshop.com/blog/avexitide-glp-1-antagonist-lucidity/) Why does avexitide block GLP-1? Explore post-bariatric hypoglycemia, LUCIDITY results and Amylyx’s November 2026 FDA-filing and conference plans. 8 November 2026 Research news · 3 min read ## [Icotrokinra and the ANTHEM-UC trial](https://europeanpeptideshop.com/blog/icotrokinra-icotyde-ulcerative-colitis-anthem-uc/) Read the ANTHEM-UC icotrokinra results: clinical response versus remission, safety findings and how ulcerative-colitis research differs from Icotyde approval. 8 November 2026 Research news · 3 min read ## [MariTide's MARITIME trial programme](https://europeanpeptideshop.com/blog/maritide-monthly-weight-loss-maritime-phase-3/) Read the November 2026 MariTide update: antibody-peptide design, MARITIME-SWITCH, earlier Phase 2 results and the limits of monthly weight-loss claims. 8 November 2026